What's new

Human medicines European public assessment report (EPAR): Winlevi, clascoterone, Status: Opinion

Human medicines European public assessment report (EPAR): Winlevi, clascoterone, Status: Opinion

Apr 30, 2025 - 09:03
 0
Human medicines European public assessment report (EPAR): Winlevi, clascoterone, Status: Opinion
Human medicines European public assessment report (EPAR): Winlevi, clascoterone, Status: Opinion
Read More

Tags:

Previous Article

Executive View: How perceptions about Chinese brands are shifting

Next Article

Daqo posts losses of US$81.5 million in Q1 as polysilicon production and sales c...

Related Posts

Opinion/decision on a Paediatric investigation plan (PIP): Enspryng, satralizumab, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Nervous system disorders;Neurology, PIP number: P/0069/2024

Opinion/decision on a Paediatric investigation plan (PI...

Apr 25, 2025  0

Human medicines European public assessment report (EPAR): Tepezza, teprotumumab, Status: Opinion

Human medicines European public assessment report (EPAR...

Apr 25, 2025  0

Business process description for PSUSA and other relate...

Apr 22, 2025  0